Newest studies

Neuromodulation and cognition in late-life depression

45/100 ✓ Peer-reviewed Risk factors Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Key finding: Late-life depression (LLD) is associated with cognitive decline and increased risk of dementia. +1 more finding

• Risk Factors

Full summary, score breakdown and related studies → Original source

NUCOG10: The development and validation of a short form of the NUCOG cognitive assessment tool

36/100 ✓ Peer-reviewed Getting a diagnosis Australian & New Zealand Journal of Psychiatry

Key finding: The psychometric properties of the Neuropsychiatry Unit Cognitive Assessment short-form versions were comparable with the original, with all maintaining high convergent validity and reliability. +4 more findings

• Diagnosis

Full summary, score breakdown and related studies → Original source

The Cost of Alzheimer Drug Treatment

41/100 ✓ Peer-reviewed Treatments Zenodo (CERN European Organization for Nuclear Research)

Key finding: Pembrolizumab was $160,00, durvalumab $115,000,Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000. +3 more findings

• Treatments
• Policy

Full summary, score breakdown and related studies → Original source

The Cost of Alzheimer Drug Treatment

29/100 ✓ Peer-reviewed Treatments Zenodo (CERN European Organization for Nuclear Research)

Key finding: Pembrolizumab was $160,00, durvalumab $115,000,Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000. +3 more findings

• Treatments
• Policy

Full summary, score breakdown and related studies → Original source

Detecting Preclinical Alzheimer’s Disease Risk in Cognitively Normal Adults Using Speech Acoustics: Validation with Plasma p-Tau217 and APOE-ε4 Status

16/100 ⚠ Preprint — not yet peer-reviewed Digital health tools medRxiv

Key finding: Spontaneous speech acoustics capture p-tau217/APOE-defined AD risk despite preserved cognition, supporting speech as a scalable, biologically grounded biomarker for preclinical AD risk stratification.

• Biomarkers
• Early Stage
• Genetics

Scored 24 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Effects of Dementia on Adverse Outcomes in Geriatric Patients Undergoing Elective Total Hip Arthroplasty: Analysis of the US Nationwide Inpatient Sample

38/100 ✓ Peer-reviewed Clinical safety Geriatric Orthopaedic Surgery & Rehabilitation

Key finding: 376 323 elective geriatric THA patient samples from the NIS database were included, with an overall dementia prevalence of 2.05%. +2 more findings

Full summary, score breakdown and related studies → Original source

Emergency Department Hallways Are Associated With Incident Delirium and Severe Agitation in Older Adults Living With Dementia

60/100 ✓ Peer-reviewed Clinical safety Journal of the American Geriatrics Society

Key finding: Our sample included 11,105 patients (median age 77, 51% female), with 2299 in the hallway group and 8806 in the non-hallway group. +4 more findings

• Care Services

Full summary, score breakdown and related studies → Original source

Dementia prevention through the eyes of individuals at risk: insights from a satisfaction survey within the programme for dementia prevention in Luxembourg

43/100 ✓ Peer-reviewed Prevention trials Frontiers in Aging

Key finding: Our study shows that the pdp is well received by its participants, underlined by a high level of satisfaction and positive responses to what pdp offers. +4 more findings

• Prevention

Full summary, score breakdown and related studies → Original source

Electrical stimulation of the vagus nerve improves amyloid pathology in delirium superimposed on dementia

40/100 ✓ Peer-reviewed Inflammation and the immune system Bioelectronic Medicine

Key finding: In AD-like mice surgery induced acute changes in amyloid-β; perioperative treatment with pVNS effectively reduced amyloid-β load, plaque sphericity, and neuronal loss. +4 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Use of explainable AI (xAI) in dementia detection and prognosis: a scoping review

57/100 ✓ Peer-reviewed Disparities BMC Medical Informatics and Decision Making

Key finding: Dementia poses a significant global health challenge for both clinicians and patients, impacting millions of individuals worldwide, yet its early diagnosis remains underexplored. +1 more finding

• Digital Tools

Full summary, score breakdown and related studies → Original source

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR ‐ SB Utilizing Semi‐Mechanistic Model

36/100 ✓ Peer-reviewed Biomarkers CPT Pharmacometrics & Systems Pharmacology

Key finding: Baseline CDR-SB was predicted by diagnosis and baseline mini-mental state examination (BMMSE) score. +4 more findings

• Brain Biology
• Clinical Trials
• Treatments

Full summary, score breakdown and related studies → Original source

Effect of prior traumatic brain injury on Alzheimer’s disease blood biomarkers in Vietnam Veterans

16/100 ⚠ Preprint — not yet peer-reviewed Biomarkers medRxiv

Key finding: In this cross-sectional study (n=272), plasma pTau217/Aβ42 ratio test accuracy was 90% in Veterans without TBI history, but was significantly lower (63-78% accuracy) in Veterans with TBI history, with lowest accuracy in those with greater TBI severity. +4 more findings

• Biomarkers

Scored 45 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Plasma p-tau217, quantified by the fully automated LUMIPULSE G platform, outperforms p-tau181 in predicting amyloid pathology in cognitive complaints patients

63/100 ✓ Peer-reviewed Biomarkers Scientific reports

Key finding: Applying the Youden-derived single p-tau217 cutoff achieved an overall agreement of 88% with CSF-defined amyloid status across both validation sets. +1 more finding

• Biomarkers

Full summary, score breakdown and related studies → Original source

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?

47/100 ✓ Peer-reviewed Treatments International journal of molecular sciences

Key finding: Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and blood-brain barrier (BBB) dysfunction. +1 more finding

• Treatments
• Brain Biology
• Genetics

Full summary, score breakdown and related studies → Original source

Classification of tauopathies from human brain homogenates through salt-modulated tau amplification

32/100 ✓ Peer-reviewed Disease mechanisms Apollo (University of Cambridge)

Key finding: This method differentiated eight tauopathies, including Alzheimer's disease, Pick disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), frontotemporal dementia with parkinsonism associated with chromosome 17 with N279K mutation (FTDP-17 N279K), and globular glial tauopathies types II and III. +4 more findings

Full summary, score breakdown and related studies → Original source

Remote digital cognitive assessment for aging and dementia using the Oxford Cognitive Testing Portal OCTAL

55/100 ✓ Peer-reviewed Getting a diagnosis npj Digital Medicine

Key finding: Four validation studies (N = 1664) confirmed cross-cultural applicability, lifespan sensitivity and clinical utility. +4 more findings

• Diagnosis

Full summary, score breakdown and related studies → Original source

The Association Between Polygenic Risk for Alzheimer's, Objective Sleep Architecture, and Plasma Neurofilament Light Chain in Midlife

38/100 ✓ Peer-reviewed Biomarkers Journal of Health Wellness and Community Research

Key finding: PRS correlated positively with log-NFL (r = 0.31, p = 0.004) and inversely with N3 duration (r = −0.26, p = 0.017). +4 more findings

• Biomarkers
• Genetics

Full summary, score breakdown and related studies → Original source

Plasma p-tau species are elevated in presymptomatic and symptomatic neuronal intranuclear inclusion disease

57/100 ✓ Peer-reviewed Biomarkers EBioMedicine

Key finding: P-tau217, p-tau231, p-tau181, α-syn, NfL, and GFAP levels were elevated in patients with NIID compared with HCs; p-tau species and GFAP were also upregulated in preNIID. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Associations of Vestibular Disorders With Risk of All‐Cause and Cause‐Specific Dementia: A Longitudinal Cohort Study in UK Biobank

50/100 ✓ Peer-reviewed Long-term cohort studies Sensory Neuroscience

Key finding: Vestibular disorders were linked to higher risks of all‐cause dementia (HR 1.86 and 95% CI 1.04–3.30), Alzheimer's disease (AD, 2.36, and 1.01–5.51), and vascular dementia (VD, 3.35, and 1.48–7.59). +4 more findings

Full summary, score breakdown and related studies → Original source

Effective deep convolutional neural network with attention mechanism for Alzheimer disease classification

37/100 ✓ Peer-reviewed Brain scans and imaging Frontiers in Radiology

Key finding: The proposed Deep-CNN and attention model focuses the model capacity on diagnostically relevant regions. +3 more findings

Full summary, score breakdown and related studies → Original source

Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes

57/100 ✓ Peer-reviewed Prevention and risk Nature Medicine

Key finding: However, metabolites associated with type 2 diabetes (T2D) risk and their determinants remain insufficiently characterized. +4 more findings

• Lifestyle
• Genetics
• Risk Factors

Full summary, score breakdown and related studies → Original source

Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia

53/100 ✓ Peer-reviewed Prevention and risk Neurology

Key finding: Across imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. +4 more findings

• Risk Factors
• Prevention
• Lifestyle

Full summary, score breakdown and related studies → Original source

Performance of ICD10 Code-Based Dementia Case Definition in the Health and Retirement Study

45/100 ✓ Peer-reviewed Costs and economics Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: STRUCTURED ABSTRACT INTRODUCTION The Dementia DataHub (DDH) reports U.S. dementia prevalence and incidence from Medicare data.

Full summary, score breakdown and related studies → Original source

Lithium therapy and delayed progression of Alzheimer’s disease and related dementias in patients with bipolar disorder and mild neurocognitive disorders

16/100 ⚠ Preprint — not yet peer-reviewed Health systems and care delivery medRxiv

Key finding: To evaluate this hypothesis in a population-based setting, we emulated a target trial comparing ADRD progression after initiation of lithium versus antiepileptic mood stabilizers among adults ≥55 years with bipolar disorder and mild neurocognitive disorder, using US Medicare claims with replication in two commercial databases. +3 more findings

Scored 27 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

The End of Life With Dementia in Asian Countries: Barriers, Facilitators and a Research Agenda for Advancing a Palliative Approach

40/100 ✓ Peer-reviewed End-of-life care Journal of the American Geriatrics Society

Key finding: Broad barriers identified in the outer setting of the implementation framework include sociocultural values and a lack of supportive policies, guidelines, and financing. +4 more findings

• End-of-Life Care

Full summary, score breakdown and related studies → Original source